Our results align with a large meta-analysis by Mascolo et al (2021),[55] which demonstrated that SGLT2 inhibitors significantly lowered the risks of MACE, myocardial infarction, HF, and all-cause mortality in diabetic patients, especially those with high cardiovascular risk. Here, SLC5A2 is linked to myocardial infarction.